No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
LYRA Lyra Therapeutics
- 0.280
- -0.017-5.69%
Close Jul 2 16:00 ET
- 0.287
- +0.007+2.54%
Post 19:42 ET
17.07MMarket Cap-239P/E (TTM)
0.299High0.280Low1.06MVolume0.299Open0.297Pre Close303.26KTurnover2.80%Turnover RatioLossP/E (Static)60.96MShares6.79052wk High0.22P/B10.54MFloat Cap0.25352wk Low--Dividend TTM37.64MShs Float22.000Historical High--Div YieldTTM6.40%Amplitude0.253Historical Low0.287Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Cantor Fitzgerald Reiterates Overweight on Lyra Therapeutics
Lyra Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/20/2024 — Cantor Fitzgerald Reiterates → Overweight 05/07/2024 666.28% HC Wainwright & Co. → $2 Downgr
Express News | Lyra Therapeutics Estimates That It Will Incur Charges Of About $3.9M-$4.1M In Connection With The Workforce Reduction; Expects That The Majority Of Charges Related To Workforce Reduction Will Be Incurred In Q2 Of 2024
Express News | Lyra Therapeutics: Expects That the Majority of Charges Related to Workforce Reduction Will Be Incurred in the Second Quarter of 2024
Express News | Lyra Therapeutics:Estimates That It Will Incur Charges of About $3.9 to $4.1 Million in Connection With the Workforce Reduction
Express News | Trading Halt: Halt Status Updated at 9:40:00 AM ET: Quotation Resumption: News and Resumption Times
Comments
$Lyra Therapeutics(LYRA.US$
The recent developments reported in Lyra Therapeutics’ latest 8-K filing present a mixed picture for investors:
Positive Aspects:
1. Cost Reduction: The workforce reduction is aimed at cutting operating expenses, which could improve the company’s financial health and increase shareholder value in the long run. This move shows the company’s proactive approach to managing costs and resources efficiently.
2. Retention of Key Executives: The approv...
The recent developments reported in Lyra Therapeutics’ latest 8-K filing present a mixed picture for investors:
Positive Aspects:
1. Cost Reduction: The workforce reduction is aimed at cutting operating expenses, which could improve the company’s financial health and increase shareholder value in the long run. This move shows the company’s proactive approach to managing costs and resources efficiently.
2. Retention of Key Executives: The approv...
5
1
$Lyra Therapeutics(LYRA.US$ .. go to de-listed?
2
1
$Lyra Therapeutics(LYRA.US$ will this ever come back?
1
2
$Lyra Therapeutics(LYRA.US$ the risk reward ...only for short term
$Lyra Therapeutics(LYRA.US$
Based on the charts and market data:
• The significant increase in short volume and short interest indicates a potential short squeeze.
• The support level is at $3.060, and the resistance is at $7.040.
• The current price action shows strong upward momentum.
Note: This analysis suggests potential for a short squeeze, but always consider the risks and do your own research before making any investment decisions. This i...
Based on the charts and market data:
• The significant increase in short volume and short interest indicates a potential short squeeze.
• The support level is at $3.060, and the resistance is at $7.040.
• The current price action shows strong upward momentum.
Note: This analysis suggests potential for a short squeeze, but always consider the risks and do your own research before making any investment decisions. This i...
6
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
还是算了 : The most important thing for pharmaceutical companies is research and development. If there are no plans for R&D now, it is chronic death